Watanabe Alexandra Sayuri, Fonseca Luiz Augusto Marcondes, Galvão Clóvis Eduardo Santos, Kalil Jorge, Castro Fabio Fernandes Morato
Universidade de São Paulo, São Paulo, Brazil.
Sao Paulo Med J. 2010 Jan;128(1):30-7. doi: 10.1590/s1516-31802010000100007.
The only effective treatment for patients who have severe reactions after Hymenoptera stings is venom immunotherapy. The aim of this study was to review the literature to assess the effects of venom immunotherapy among patients presenting severe reactions after Hymenoptera stings.
Randomized controlled trials in the worldwide literature were reviewed. The manuscript was produced in the Discipline of Allergy and Clinical Immunology, Universidade de São Paulo (USP).
Randomized controlled trials involving venom immunotherapy versus placebo or only patient follow-up were evaluated. The risk of systemic reactions after specific immunotherapy was evaluated by calculating odds ratios (OR) and their 95% confidence intervals.
2,273 abstracts were identified by the keywords search. Only four studies were included in this review. The chi-square test for heterogeneity showed that two studies were homogeneous and could be included in a meta-analysis. By combining the two studies, the odds ratio became significant: 0.29 (0.10-0.87). However, analysis on the severity of the reactions after immunotherapy showed that the benefits may not be so significant because the reactions were mostly similar to or milder than the original reaction.
Specific immunotherapy should be recommended for adults and children with moderate to severe reactions, but there is no need to prescribe it for children with skin reactions alone, especially if the exposure is very sporadic. On the other hand, the risk-benefit relation should always be assessed in each case.
对于膜翅目昆虫叮咬后出现严重反应的患者,唯一有效的治疗方法是毒液免疫疗法。本研究的目的是回顾文献,评估毒液免疫疗法对膜翅目昆虫叮咬后出现严重反应的患者的疗效。
回顾了全球文献中的随机对照试验。该手稿由圣保罗大学(USP)过敏与临床免疫学学科撰写。
评估了涉及毒液免疫疗法与安慰剂或仅患者随访的随机对照试验。通过计算比值比(OR)及其95%置信区间来评估特异性免疫疗法后全身反应的风险。
通过关键词搜索识别出2273篇摘要。本综述仅纳入了四项研究。异质性的卡方检验表明,两项研究具有同质性,可纳入荟萃分析。合并这两项研究后,比值比变得显著:0.29(0.10 - 0.87)。然而,对免疫疗法后反应严重程度的分析表明,益处可能并不那么显著,因为反应大多与原始反应相似或比原始反应更轻。
对于有中度至重度反应的成人和儿童,应推荐特异性免疫疗法,但对于仅出现皮肤反应的儿童,尤其是暴露非常偶发的情况,无需开具此疗法。另一方面,应始终在每个病例中评估风险效益关系。